- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Curr Drug Targets. 2018 Sep 10;:
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol. 2018 Aug 28;:JCO2018783118
Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk.
Nat Commun. 2018 Aug 13;9(1):3221
BMC Med Genomics. 2018 Aug 09;11(1):65
The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Lung Cancer. 2018 Sep;123:22-29
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.
Curr Oncol. 2018 Jun;25(Suppl 1):S28-S37
Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-small-cell Lung Cancer (NCT02788461).
Clin Lung Cancer. 2018 May 16;:
Oncotarget. 2018 Apr 27;9(32):22559-22570
Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.
CNS Drugs. 2018 May 24;:
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group